Advertisement
Mayo Clinic Proceedings Home

Risk of Venous Thromboembolism in Men Receiving Testosterone Therapy

      Abstract

      Objective

      To examine the risk of venous thromboembolism (VTE) associated with exposure to testosterone therapy in middle-aged and older men.

      Patients and Methods

      We conducted a case-control study of 30,572 men 40 years and older who were enrolled in one of the nation’s largest commercial insurance programs between January 1, 2007, and December 31, 2012. Cases were defined as men who had a primary diagnosis of VTE and received an anticoagulant drug in the 60 days after their diagnoses. Cases were matched with 3 controls on event/index month, age, geographic region, diagnosis of hypogonadism, and diagnosis of any underlying prothrombotic condition. Conditional logistic regression analysis was used to calculate adjusted odds ratios (aORs) and 95% CIs for the risk of VTE associated with previous exposure to testosterone therapy.

      Results

      Exposure to testosterone therapy in the 15 days before the event/index date was not associated with an increased risk of VTE (aOR, 0.90; 95% CI, 0.73-1.12). None of the specific routes of administration examined were associated with an increased risk of VTE (topical [aOR, 0.80; 95% CI, 0.61-10.41], transdermal [aOR, 0.91; 95% CI, 0.38-2.16], and intramuscular [aOR, 1.15; 95% CI, 0.80-1.64]). These findings persisted using exposure windows that extended to 30 and 60 days before the event/index date.

      Conclusion

      Having filled a prescription for testosterone therapy was not associated with an increased risk of VTE in commercially insured middle-aged and older men. These findings may provide clinically relevant information about the benefit-risk assessment for men with testosterone deficiency considering treatment.

      Abbreviations and Acronyms:

      aOR (adjusted odds ratio), CDM (Clinformatics Data Mart), DVT (deep vein thrombosis), FDA (Food and Drug Administration), ICD-9-CM (International Classification of Diseases, Ninth Revision, Clinical Modification), NSAID (nonsteroidal anti-inflammatory drug), PE (pulmonary embolism), VTE (venous thromboembolism)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Baillargeon J.
        • Urban R.J.
        • Ottenbacher K.J.
        • Pierson K.S.
        • Goodwin J.S.
        Trends in androgen prescribing in the United States, 2001-2011.
        JAMA Intern Med. 2013; 173: 1465-1466
        • Glueck C.J.
        • Wang P.
        Testosterone therapy, thrombosis, thrombophilia, cardiovascular events.
        Metabolism. 2014; 63: 989-994
        • Glueck C.J.
        • Richardson-Royer C.
        • Schultz R.
        • et al.
        Testosterone therapy, thrombophilia-hypofibrinolysis, and hospitalization for deep venous thrombosis-pulmonary embolus: an exploratory, hypothesis-generating study.
        Clin Appl Thromb Hemost. 2014; 20: 244-249
        • Glueck C.J.
        • Bowe D.
        • Valdez A.
        • Wang P.
        Thrombosis in three postmenopausal women receiving testosterone therapy for low libido.
        Womens Health (Lond Engl). 2013; 9: 405-410
      1. Testosterone products: FDA/CDER statement—risk of venous blood clots. US Food and Drug Administration website. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm402054.htm. Published June 20, 2014. Accessed October 5, 2014.

      2. Summary safety review—testosterone replacement products—cardiovascular risk. Health Canada website. http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/testosterone-eng.php. Published July 15, 2014. Accessed October 10, 2014.

        • Fernández-Balsells M.M.
        • Murad M.H.
        • Lane M.
        • et al.
        Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis.
        J Clin Endocrinol Metab. 2010; 95: 2560-2575
        • Heufelder A.E.
        • Saad F.
        • Bunck M.C.
        • Gooren L.
        Fifty-two-week treatment with diet and excercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and abnormal plasma testosterone.
        J Androl. 2009; 30: 726-733
        • Saad F.
        Androgen therapy in men with testosterone deficiency: can testosterone reduce the risk of cardiovascular disease?.
        Diabetes Metab Res Rev. 2012; 28: 52-59
        • Hulley S.
        • Grady D.
        • Bush T.
        • et al.
        Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women.
        JAMA. 1998; 280: 605-613
        • Lidegaard Ø.
        • Løkkegaard E.
        • Jenson A.
        • Skovlund C.W.
        • Keiding N.
        Thrombotic stroke and myocardial infarction with hormonal contraception.
        N Engl J Med. 2012; 366: 2257-2266
        • Holmegard H.N.
        • Nordestgaard B.G.
        • Schonohr P.
        • Tybjaerg-Hansen A.
        • Benn M.
        Endogenous sex hormones and risk of venous thromboembolism in women and men.
        J Thromb Haemost. 2014; 12: 297-305
        • Svartberg J.
        • Braekkan S.K.
        • Laughlin G.A.
        • Hansen J.B.
        Endogenous sex hormone levels in men are not associated with risk of venous thromboembolism: the Tromso study.
        Eur J Endocrinol. 2009; 160: 833-838
      3. LeWine H. FDA warns about blood clot risk with testosterone products. Harvard Health Publications website. http://www.health.harvard.edu/blog/fda-warns-blood-clot-risk-testosterone-products-201406247240. Published June 24, 2014. Accessed August 1, 2014.

        • Ziyadeh N.
        • Fife D.
        • Walker A.M.
        • Wilkinson G.S.
        • Seeger J.D.
        A matched cohort study of the risk of cancer in users of becaplermin.
        Adv Skin Wound Care. 2011; 24: 31-39
        • Loughlin J.
        • Quinn S.
        • Rivero E.
        • et al.
        Tegaserod and the risk of cardiovascular ischemic events: an observational cohort study.
        J Cardiovasc Pharmacol Ther. 2010; 15: 151-157
        • Loughlin J.
        • Seeger J.D.
        • Eng P.M.
        • et al.
        Risk of hyperkalemia in women taking ethinylestradiol/drospirenone and other oral contraceptives.
        Contraception. 2008; 78: 377-383
        • Seeger J.D.
        • Loughlin J.
        • Eng P.M.
        • Clifford C.R.
        • Cutone J.
        • Walker A.M.
        Risk of thromboembolism in women taking ethinyestradiol/drospirenone.
        Obstet Gynecol. 2007; 110: 587-593
        • Elixhauser A.
        • Steiner C.
        • Harris D.R.
        • Coffey R.M.
        Comorbidity measures for use with administrative data.
        Med Care. 1998; 36: 8-27
        • Klabunde C.N.
        • Warren J.L.
        • Legler J.M.
        Assessing comorbidity using claims data: an overview.
        Med Care. 2002; 40 (IV-26-IV-35)
        • Ajayi A.A.
        • Mathur R.
        • Halushka P.V.
        Testosterone increases human platelet thromboxane A2 receptor density and aggregation responses.
        Circulation. 1995; 91: 2742-2747
        • Swerdloff R.S.
        • Wang C.
        Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel.
        Aging Male. 2003; 6: 207-211
        • Høibraaten E.
        • Qvigstad E.
        • Anderson T.O.
        • Mowinckel M.C.
        • Sandset P.M.
        The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism—results from a randomized, double-blind, clinical trial.
        Thromb Haemost. 2001; 85: 775-881
        • Friedman J.
        • Glueck C.J.
        • Prince M.
        • Riaz R.
        • Wang P.
        Testosterone, thrombophilia, thrombosis.
        Transl Res. 2015; 165: 537-548
        • White R.H.
        • Keenan C.R.
        Effects of race and ethnicity on the incidence of venous thromboembolism.
        Thromb Res. 2009; 123: S11-S17
        • Zakai N.A.
        • McClure L.A.
        Racial differences in venous thromboembolism.
        J Thromb Haemost. 2011; 9: 1877-1882
        • Cheng Y.J.
        • Liu Z.H.
        • Yao F.J.
        • et al.
        Current and former smoking and risk for venous thromboembolism: a systematic review and meta-analysis.
        PLoS Med. 2013; 10: e10001515